Vision or voodoo? Biotech IPO master Vivek Ramaswamy is still setting up new biotechs and hatching more deals
In the 18 months since Vivek Ramaswamy blindsided the biotech industry with a record-setting IPO for the mystery biotech Axovant, the one-time hedge fund maestro turned drug entrepreneur has set up three more companies and taken one of them public at near supersonic speed, all while busily in-licensing drugs from a growing list of suppliers.
And he isn’t slowing down. In a sitdown with me at JP Morgan this week, Ramaswamy says he may well uncork another startup and strike up another three or four deals in 2017.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.